![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.75 | -4.69% | 15.25 | 15.00 | 15.50 | 16.25 | 15.25 | 16.25 | 209,970 | 09:00:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.37 | 13.91M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/10/2017 09:10 | Hi all, I asked Stephen about this and he said:"Our stated aim is to continue to build value in OptiBiotix and this next phase, the commercial phase, is where we see some of the greatest potential for an uplift in value. Whilst we have interest from pharma we would look to work with pharma under license or joint development arrangements to exploit this opportunity. As such we have no plans to sell out to pharma or anyone else before the potential of our technology and products is achieved." | ![]() primal123 | |
19/10/2017 08:48 | My point is a pharma company is likely to be interested in one division - which would be sold at a premium - and at least the other divisions would remain. Which is much better than the whole company being taken out at an early stage in one go. A 30K buy went through on nex early doors... | ![]() parob | |
19/10/2017 08:36 | If pharma interest is as prominent as indicated by recent details here, we would end up in the middle of a bidding war irrespective of being split into divisions. In fact each separate division would be less able to defend its independence.All IMVHO | ![]() aspex | |
19/10/2017 08:32 | That's another good reason for splitting and listing each division separately IMO. | ![]() parob | |
19/10/2017 08:07 | What worries me is if big pharma are sniffing around we could find ourselves on the end of a bid before our potential is reached. I also dont see any defence against a bid as we have few IIs, thoughts.. | ![]() zebbo | |
18/10/2017 23:54 | John, don't stress on the side effects unfortunately it's normal... But fortunately it did blow over so to speak :-)) | ![]() 1bokke | |
18/10/2017 23:37 | Funny how life goes. Before I got (and acted on) this tip in the Penny Share Letter, I'd honestly never heard of the word Microbiome before. NOW it seems that every day Parob, Primal, Elrico or someone else unearths yet another new article Every day. It strikes me that this Can't continue without our company making some fantastic headway. I just can't see how Opti, being positioned as it is, can't take centre stage in all of this narrative, and have some serious re-rating. I keep wondering, is there something untoward that we're missing, which the Institutional Investors have spotted?? I can't think of anything. Even my lovely wife is starting to spot articles in the newspapers on the Microbiome! There might be one downside which we haven't been made aware of. . . . Since starting this Go Figure regime, I'm seriously concerned at the affect I'm having on the Ozone layer, with all the methane I'm producing !! Oh dear. John | ![]() 2350220 | |
18/10/2017 19:18 | Bit more on the antibiotic / microbiome topic Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing? Directors Talk article: Did you know that bacteria have antibacterial properties? Its true. We spoke to Dr Catherine O'neill CEO of Skinbiotix Plc (LON:SBTX) who said, ‘Its worth remembering that penicillin, one of the first antibiotics to be used medically, is derived from a mould. Micro-organisms make antibacterial compounds against each other. Against this background, the hope is that new antibiotics will be discovered in the human microbiome that will help in the fight against antibiotics resistance.’ In a world where antibiotic resistance is becoming a major problem, scientists race in search for alternatives. Could bacteria provide much-needed strategies to prevent life-threatening infections? The following article provides valuable insight into this and more: | ![]() onedayrodders | |
18/10/2017 18:57 | Or a looky chump there Elrico, lol! Very interesting, look forward to hearing of developments in due course, thanks for your opinions! | ![]() devonlad | |
18/10/2017 18:26 | Absolutely Elrico."Optibiotix had seen big pharma interest "build" over the past 3-4 months"This suggests conversations have been taking place for a quite a while. | ![]() parob | |
18/10/2017 18:14 | Most definitely mate!!! | ![]() shrewdmole | |
18/10/2017 18:02 | Does anyone else have a feeling SOH is trying to offer us a clue with todays Proactive interview? SOH usually comments on updates, etc. This seems to have a specific agenda centred around big pharmas interest in LP-LDL. No I have not asked as this would be futile and make me luck a right chump ;) | elrico | |
18/10/2017 16:07 | Comment from SOH on an unrelated topic I had put to me for SOH related to antibiotics. "We can’t create new antibiotics but their is growing evidence to suggest that by modifying the microbiome you can increase the effectiveness of a range of therapeutics. In the last few months the level of interest in this area has increased as pharma companies have recognised the potential but also as a result of some high profile failings in drug development." "We do not intend to enter the pharma market but I have built the company using pharma platforms and covered medical applications in our patent applications so we can partner or license out our technology if the opportunity arises." Clearly, OPTI have IP ready for pharmaceutical platforms. This is a huge plus for the likes of pharma seeking new drugs and or increase the life of existing drugs because most of the work has been conducted for them. It would save them £ms in R&D and time and most likely a much quicker route to market. What I don't understand at this stage, is how an OTC GRAS scientifically proven products' route to becoming a key ingredient in a pharmaceutical products? It would be really useful to know the key stages a pharma products route to markets (assuming all is successful) from initial R&D right through to phases 1-3 to final approval from regulatory bodies. Time consuming and expensive for sure! | elrico | |
18/10/2017 16:00 | Semper, Prob both but if Doctor's prescribe surely sales would go through the roof? | ![]() deeppockets | |
18/10/2017 15:19 | Deep - would a prescription be needed or just OTC? | ![]() semper vigilans | |
18/10/2017 15:14 | Good tip! thanks John :) | smegfish | |
18/10/2017 15:03 | So it looks like SOH is saying they are in serious discussions with big pharma! That's amazing! How about LP-LDL being prescribed by doctors for cholesterol? Bingo! | ![]() deeppockets | |
18/10/2017 14:29 | Thanks to everyone who post such interesting articles. Great to see how the World is waking up to this fantastic story unfolding in front of our eyes. I would like to offer a very simple tip for anyone posting Web links though: If you Capitalise the first H in Http it stops ADVFN from changing it to hxxp, and so keeps it as a clickable link. That saves folk having to copy and past the address, and change the hxxp bit themselves. John | ![]() 2350220 | |
18/10/2017 13:24 | Yet more microbiome news.. hxxps://www.scienced | smegfish | |
18/10/2017 13:10 | Nice one! 👍 | joyjoy13 | |
18/10/2017 12:56 | Excellent. Good find primal. So combining with LP-LDL could help extend the patent life of existing drugs. No wonder pharma company interest is increasing. Looks like Nicktopten's blood pressure reduction is being used as an example! Had a quick look on OPTI's website, but can't see it mentioned - can anyone else? | ![]() parob | |
18/10/2017 12:52 | No problem! :) Cannot believe people are selling at this vital period! Each to their own though! As Elrico and Shrewdmole have said we are now reaching that inflection point! | ![]() primal123 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions